Memantina Teva (Memantine Hydrochloride)

Memantina is a NMDA receptor antagonist used in the management of Alzheimer’s disease and its associated symptoms.

• Moderate Alzheimer’s disease: improves cognition and daily functioning.
• Severe Alzheimer’s disease: may help maintain basic activities of daily living.
• Behavioral symptoms of Alzheimer’s disease: can reduce agitation and aggression.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by overstimulation with glutamate, thereby reducing excitotoxic neuronal damage and modulating synaptic transmission involved in learning and memory.

Memantina may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient cranial pain.
• Constipation: reduced bowel movements.
• Confusion: temporary disorientation.
• Hypertension: elevated blood pressure readings.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Seizures: new‑onset convulsive episodes.
• Cardiac arrhythmias: irregular heart rhythms.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Suicidal thoughts: emergence of depressive ideation.
• Respiratory depression: reduced breathing effort.

When prescribing Memantina, several safety considerations should be observed.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• History of seizures: use with caution and monitor neurologic status.
• Concurrent use with other NMDA antagonists: avoid additive neurotoxicity.
• Pregnancy and breastfeeding: safety not established; weigh potential risks and benefits.
• Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Memantina can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid)

• Amantadine: increased risk of neurotoxicity when combined.
• Other NMDA antagonists: additive antagonistic effect may lead to excessive inhibition.
• Strong CYP450 inducers (e.g., carbamazepine): may lower memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may diminish the cognitive benefits of memantine.
• Diuretics: can increase the likelihood of hypotension.
• Antihypertensives: monitor blood pressure for additive lowering effect.